# A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis

> **NCT07549984** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 16 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** IBI3033
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07549984
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-02-10
- **Final completion:** 2027-03-25
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549984, "A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07549984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*